These studies are devoted to increasing our understanding of the mechanisms of hepatocellular transformation. In primary hepatocytes and HepG2 hepatoma cells, prolonged Mitogen Activated Protein (MAP) kinase activation increased expression of cyclin dependent kinase inhibitor (cdki) proteins and reduced DNA synthesis. However, the amount of MAP kinase activity required to increase cdki expression and inhibit DNA synthesis had increased at least 6-fold in the hepatoma cells. Thus one mechanism by which loss of growth control and hepatocellular transformation may take place is by a reduced ability of MAP kinase signaling to cause increased cdki protein levels. i.e. the threshold MAP kinase activity required to elevate p2l Cip-1 expression has increased in the hepatoma cells. The likely candidate molecules for this alteration in the threshold are downstream of MAP kinase signaling and upstream of the cdki proteins. The tumor suppresser p53 is unlikely to be a candidate because both primary hepatocytes and HepG2 cells express functional p53.
The aim of this work is to understand in primary hepatocytes the mechanisms downstream of the MAP kinase cascade by which this pathway signals to increase the expression of the cdki proteins p2l Cip-1 and p16 INK4a. We will determine using knock-out mice and anti-sense technologies whether chronic MAP kinase signaling can (a) force primary hepatocytes into S phase in the absence of either p2l Cip-1/WAF1 or p16 INK4a expression, and (b) increase p2l Cip-1 and p16 INK4a protein levels by increasing the rates of transcription and/or translation, or by increasing the stabilities of p2l Cip-1/p16 INK4a mRNA and/or protein. We will determine whether the increased protein levels of p2l Cip-1 due to chronic activation of the MAP kinase cascade in primary hepatocytes is/are mediated by the transcription factors C/EBPalpha, C/EBPbeta, Sp1, and Sp3. It is only by understanding the signaling mechanisms which regulate growth arrest in primary hepatocytes that we may begin to understand what has become defective within these mechanisms in hepatoma cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK052825-02
Application #
6177910
Study Section
Cellular Biology and Physiology Subcommittee 1 (CBY)
Program Officer
Serrano, Jose
Project Start
1999-05-01
Project End
2004-04-30
Budget Start
2000-05-01
Budget End
2001-04-30
Support Year
2
Fiscal Year
2000
Total Cost
$179,220
Indirect Cost
Name
Virginia Commonwealth University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Booth, Laurence; Roberts, Jane L; Tavallai, Mehrad et al. (2016) The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget 7:19620-30
Tavallai, Mehrad; Booth, Laurence; Roberts, Jane L et al. (2016) Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS. Oncotarget 7:17290-300
Booth, Laurence; Albers, Thomas; Roberts, Jane L et al. (2016) Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo. Oncotarget 7:40398-40417
Booth, Laurence; Roberts, Jane L; Tavallai, Mehrad et al. (2015) OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies. J Cell Physiol 230:1982-98
Webb, Timothy; Carter, Jori; Roberts, Jane L et al. (2015) Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance. Cancer Biol Ther 16:1660-70
Tavallai, Mehrad; Hamed, Hossein A; Roberts, Jane L et al. (2015) Nexavar/Stivarga and viagra interact to kill tumor cells. J Cell Physiol 230:2281-98
Hamed, Hossein A; Tavallai, Seyedmehrad; Grant, Steven et al. (2015) Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. J Cell Physiol 230:131-9
Roberts, Jane L; Tavallai, Mehrad; Nourbakhsh, Aida et al. (2015) GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases. J Cell Physiol 230:2552-78
Goodson 3rd, William H; Lowe, Leroy; Carpenter, David O et al. (2015) Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis 36 Suppl 1:S254-96
Booth, Laurence; Roberts, Jane L; Cruickshanks, Nichola et al. (2015) PDE5 inhibitors enhance celecoxib killing in multiple tumor types. J Cell Physiol 230:1115-27

Showing the most recent 10 out of 165 publications